Sector News

Integra LifeSciences Acquires Metasurg’s Foot and Ankle Product Portfolio

January 13, 2015
Life sciences
(GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation today announced that, in December, it closed on the acquisition of the product portfolio from Metasurg.
 
The addition of the Metasurg product portfolio enhances Integra’s lower extremity product offering with easy to use implant systems. It also offers the opportunity to distribute a biologic allograft derived from human placental tissue as a possible complement to Integra’s wound care product offering.
 
Revenues in 2013 were approximately $6 million, with growth in the double digits over the prior year period. The Company expects minimal impact on profits in 2015 and slower growth during the transition period, before returning to double digit growth longer term.
 
Metasurg was founded in 2005 in Houston, TX, with the goal of providing foot and ankle surgeons intuitive, easy-to-use implant systems. The Company has commercialized a variety of implant systems, launching five products over the last several years. The acquired portfolio includes the DigiFuse ® Cannulated Intramedullary Fusion System, MemoFix ® Super Elastic Nitinol Staple System, Ti6® screw portfolio, BioMotion® 1st MPJ Hemi System and TruArch® Subtalar Implant System. In addition to these implants, the acquisition also offers Integra the opportunity to distribute an amniotic product line called BioFix ® Regenerative Biologics.
 
Source: Integra
 

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach